HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Nobuhiko Ishizuka Selected Research

Nicorandil (SG 75)

3/2015Nicorandil prevents sirolimus-induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation.
1/2013Nicorandil ameliorated hypertensive renal injury without lowering blood pressure in spontaneously hypertensive rats.
1/2011Nicorandil prevents endothelial dysfunction due to antioxidative effects via normalisation of NADPH oxidase and nitric oxide synthase in streptozotocin diabetic rats.
9/2009Nicorandil improves glomerular injury in rats with mesangioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors.
3/2009Nicorandil attenuates FeCl(3)-induced thrombus formation through the inhibition of reactive oxygen species production.
11/2008Nicorandil, a potassium channel opener and nitric oxide donor, improves the frequent urination without changing the blood pressure in rats with partial bladder outlet obstruction.
2/2008Inhibitory effects of nicorandil, a K ATP channel opener and a nitric oxide donor, on overactive bladder in animal models.
1/2008Nicorandil enhances the effect of endothelial nitric oxide under hypoxia-reoxygenation: role of the KATP channel.
11/2002Nicorandil and leukocyte activation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password:


Nobuhiko Ishizuka Research Topics

Disease

2Thrombosis (Thrombus)
03/2015 - 03/2009
2Proteinuria
01/2013 - 09/2009
2Urinary Bladder Neck Obstruction (Bladder Neck Obstruction)
11/2008 - 02/2008
1Fibrosis (Cirrhosis)
01/2013
1Inflammation
04/2011
1Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
04/2011
1Hypertension (High Blood Pressure)
04/2011
1Cardiovascular Diseases (Cardiovascular Disease)
01/2011
1Hypertrophy
09/2009
1Nephritis
09/2009
1Heart Failure
09/2009
1Glomerulonephritis
09/2009
1Kidney Diseases (Kidney Disease)
09/2009
1Heart Diseases (Heart Disease)
02/2008
1Overactive Urinary Bladder (Overactive Bladder)
02/2008
1Urethral Obstruction
02/2008
1Anoxia (Hypoxia)
01/2008
1Ischemia
11/2002
1Myocardial Infarction
11/2002

Drug/Important Bio-Agent (IBA)

9Nicorandil (SG 75)IBA
03/2015 - 11/2002
4Nitric Oxide (Nitrogen Monoxide)FDA Link
11/2008 - 11/2002
3Adenosine Triphosphate (ATP)IBA
02/2008 - 11/2002
2Reactive Oxygen Species (Oxygen Radicals)IBA
03/2015 - 03/2009
2PotassiumIBA
02/2008 - 11/2002
1Sirolimus (Rapamycin)FDA Link
03/2015
1Nitric Oxide Synthase Type III (Endothelial Nitric Oxide Synthase)IBA
01/2013
1Messenger RNA (mRNA)IBA
01/2013
1Endothelins (Endothelin)IBA
01/2013
1SodiumIBA
04/2011
1N,N-dimethylarginine (asymmetric dimethylarginine)IBA
04/2011
1Parathyroid Hormone (Parathormone)IBA
04/2011
1CreatinineIBA
04/2011
1Interleukin-6 (Interleukin 6)IBA
04/2011
1PhosphorusIBA
04/2011
1Cardiotonic Agents (Cardiac Stimulants)IBA
09/2009
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
09/2009
1KATP ChannelsIBA
03/2009
1Potassium Channels (Potassium Channel)IBA
11/2008
1Nitric Oxide Synthase (NO Synthase)IBA
02/2008
1Acetic Acid (Vinegar)FDA LinkGeneric
02/2008
1Superoxides (Superoxide)IBA
01/2008